PDCD1 and Hodgkins lymphoma: A clinical investigation involving Hodgkin lymphoma patients receiving allo-HSCT post-anti-PD-1 therapy demonstrated a direct correlation between extended treatment-transplantation intervals and reduced GVHD incidence (28).